Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin
Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presente...
Gespeichert in:
| Veröffentlicht in: | Veterinary & comparative oncology 2010-06, Vol.8 (2), p.81-86 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 86 |
|---|---|
| container_issue | 2 |
| container_start_page | 81 |
| container_title | Veterinary & comparative oncology |
| container_volume | 8 |
| creator | Kelly, J.M Belding, B.A Schaefer, A.K |
| description | Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow-up time of 842 days. Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA. |
| doi_str_mv | 10.1111/j.1476-5829.2010.00208.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_745636493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>745636493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5118-28e559b9d259b57022e84ae28880bcfe268fd4c43f6bbad653179800e4f0c38f3</originalsourceid><addsrcrecordid>eNqNkM1O3DAUha2qVaHTvkKbXVcZ_B9H6gaNWqgEZUEBic2VkzjgqRNT2yNm3r4OgdkWL-yr6--cax-ECoKXJK-j9ZLwSpZC0XpJce5iTLFabt-gw_3F231N8AH6EOM6Q5Qz-h4dUCyqmlF8iE6PWz2mez_o5Dex0INxvnE6ptwp7Fh0_i4WKRidTFc82nSfmyloZ6L1o3ZF44wfdq0dP6J3vXbRfHo-F-jqx_ffq9Py7OLk5-r4rGwFIaqkyghRN3VH8y6q_CKjuDZUKYWbtjdUqr7jLWe9bBrdScFIVSuMDe9xy1TPFujr7PsQ_N-NiQkGG1vjnB5N_gFUXEgmec3-TzLGJREZXyA1k23wMQbTw0Owgw47IBimwGENU5Yw5QpT4PAUOGyz9PPzkE0zmG4vfEk4A99m4NE6s3u1MVyvLnKR5eUstzGZ7V6uwx-QFasE3Pw6gevb25v6XNUwjfsy8732oO-CjXB1mY0ZJoozxSX7B4Q_ptc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733461556</pqid></control><display><type>article</type><title>Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kelly, J.M ; Belding, B.A ; Schaefer, A.K</creator><creatorcontrib>Kelly, J.M ; Belding, B.A ; Schaefer, A.K</creatorcontrib><description>Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow-up time of 842 days. Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.</description><identifier>ISSN: 1476-5810</identifier><identifier>EISSN: 1476-5829</identifier><identifier>DOI: 10.1111/j.1476-5829.2010.00208.x</identifier><identifier>PMID: 20579320</identifier><language>eng</language><publisher>Oxford, UK: Oxford, UK : Blackwell Publishing Ltd</publisher><subject>acanthomatous ameloblastoma ; acanthomatous epulis ; adverse effects ; Ameloblastoma - drug therapy ; Ameloblastoma - veterinary ; animal injuries ; Animals ; Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - therapeutic use ; antineoplastic agents ; bleomycin ; Bleomycin - administration & dosage ; Bleomycin - adverse effects ; Bleomycin - therapeutic use ; chemotherapy ; dog diseases ; Dog Diseases - drug therapy ; Dogs ; drug injection ; drug toxicity ; Female ; gingiva ; Gingival Neoplasms - drug therapy ; Gingival Neoplasms - veterinary ; infection ; Injections, Intralesional - veterinary ; intralesional chemotherapy ; lesions (animal) ; Male ; neoplasms ; Retrospective Studies ; swelling (physiological) ; Treatment Outcome</subject><ispartof>Veterinary & comparative oncology, 2010-06, Vol.8 (2), p.81-86</ispartof><rights>2010 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5118-28e559b9d259b57022e84ae28880bcfe268fd4c43f6bbad653179800e4f0c38f3</citedby><cites>FETCH-LOGICAL-c5118-28e559b9d259b57022e84ae28880bcfe268fd4c43f6bbad653179800e4f0c38f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1476-5829.2010.00208.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1476-5829.2010.00208.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20579320$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kelly, J.M</creatorcontrib><creatorcontrib>Belding, B.A</creatorcontrib><creatorcontrib>Schaefer, A.K</creatorcontrib><title>Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin</title><title>Veterinary & comparative oncology</title><addtitle>Vet Comp Oncol</addtitle><description>Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow-up time of 842 days. Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.</description><subject>acanthomatous ameloblastoma</subject><subject>acanthomatous epulis</subject><subject>adverse effects</subject><subject>Ameloblastoma - drug therapy</subject><subject>Ameloblastoma - veterinary</subject><subject>animal injuries</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>antineoplastic agents</subject><subject>bleomycin</subject><subject>Bleomycin - administration & dosage</subject><subject>Bleomycin - adverse effects</subject><subject>Bleomycin - therapeutic use</subject><subject>chemotherapy</subject><subject>dog diseases</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>drug injection</subject><subject>drug toxicity</subject><subject>Female</subject><subject>gingiva</subject><subject>Gingival Neoplasms - drug therapy</subject><subject>Gingival Neoplasms - veterinary</subject><subject>infection</subject><subject>Injections, Intralesional - veterinary</subject><subject>intralesional chemotherapy</subject><subject>lesions (animal)</subject><subject>Male</subject><subject>neoplasms</subject><subject>Retrospective Studies</subject><subject>swelling (physiological)</subject><subject>Treatment Outcome</subject><issn>1476-5810</issn><issn>1476-5829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1O3DAUha2qVaHTvkKbXVcZ_B9H6gaNWqgEZUEBic2VkzjgqRNT2yNm3r4OgdkWL-yr6--cax-ECoKXJK-j9ZLwSpZC0XpJce5iTLFabt-gw_3F231N8AH6EOM6Q5Qz-h4dUCyqmlF8iE6PWz2mez_o5Dex0INxvnE6ptwp7Fh0_i4WKRidTFc82nSfmyloZ6L1o3ZF44wfdq0dP6J3vXbRfHo-F-jqx_ffq9Py7OLk5-r4rGwFIaqkyghRN3VH8y6q_CKjuDZUKYWbtjdUqr7jLWe9bBrdScFIVSuMDe9xy1TPFujr7PsQ_N-NiQkGG1vjnB5N_gFUXEgmec3-TzLGJREZXyA1k23wMQbTw0Owgw47IBimwGENU5Yw5QpT4PAUOGyz9PPzkE0zmG4vfEk4A99m4NE6s3u1MVyvLnKR5eUstzGZ7V6uwx-QFasE3Pw6gevb25v6XNUwjfsy8732oO-CjXB1mY0ZJoozxSX7B4Q_ptc</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>Kelly, J.M</creator><creator>Belding, B.A</creator><creator>Schaefer, A.K</creator><general>Oxford, UK : Blackwell Publishing Ltd</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>201006</creationdate><title>Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin</title><author>Kelly, J.M ; Belding, B.A ; Schaefer, A.K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5118-28e559b9d259b57022e84ae28880bcfe268fd4c43f6bbad653179800e4f0c38f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>acanthomatous ameloblastoma</topic><topic>acanthomatous epulis</topic><topic>adverse effects</topic><topic>Ameloblastoma - drug therapy</topic><topic>Ameloblastoma - veterinary</topic><topic>animal injuries</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>antineoplastic agents</topic><topic>bleomycin</topic><topic>Bleomycin - administration & dosage</topic><topic>Bleomycin - adverse effects</topic><topic>Bleomycin - therapeutic use</topic><topic>chemotherapy</topic><topic>dog diseases</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>drug injection</topic><topic>drug toxicity</topic><topic>Female</topic><topic>gingiva</topic><topic>Gingival Neoplasms - drug therapy</topic><topic>Gingival Neoplasms - veterinary</topic><topic>infection</topic><topic>Injections, Intralesional - veterinary</topic><topic>intralesional chemotherapy</topic><topic>lesions (animal)</topic><topic>Male</topic><topic>neoplasms</topic><topic>Retrospective Studies</topic><topic>swelling (physiological)</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kelly, J.M</creatorcontrib><creatorcontrib>Belding, B.A</creatorcontrib><creatorcontrib>Schaefer, A.K</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Veterinary & comparative oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelly, J.M</au><au>Belding, B.A</au><au>Schaefer, A.K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin</atitle><jtitle>Veterinary & comparative oncology</jtitle><addtitle>Vet Comp Oncol</addtitle><date>2010-06</date><risdate>2010</risdate><volume>8</volume><issue>2</issue><spage>81</spage><epage>86</epage><pages>81-86</pages><issn>1476-5810</issn><eissn>1476-5829</eissn><abstract>Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow-up time of 842 days. Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.</abstract><cop>Oxford, UK</cop><pub>Oxford, UK : Blackwell Publishing Ltd</pub><pmid>20579320</pmid><doi>10.1111/j.1476-5829.2010.00208.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-5810 |
| ispartof | Veterinary & comparative oncology, 2010-06, Vol.8 (2), p.81-86 |
| issn | 1476-5810 1476-5829 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_745636493 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | acanthomatous ameloblastoma acanthomatous epulis adverse effects Ameloblastoma - drug therapy Ameloblastoma - veterinary animal injuries Animals Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use antineoplastic agents bleomycin Bleomycin - administration & dosage Bleomycin - adverse effects Bleomycin - therapeutic use chemotherapy dog diseases Dog Diseases - drug therapy Dogs drug injection drug toxicity Female gingiva Gingival Neoplasms - drug therapy Gingival Neoplasms - veterinary infection Injections, Intralesional - veterinary intralesional chemotherapy lesions (animal) Male neoplasms Retrospective Studies swelling (physiological) Treatment Outcome |
| title | Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A53%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acanthomatous%20ameloblastoma%20in%20dogs%20treated%20with%20intralesional%20bleomycin&rft.jtitle=Veterinary%20&%20comparative%20oncology&rft.au=Kelly,%20J.M&rft.date=2010-06&rft.volume=8&rft.issue=2&rft.spage=81&rft.epage=86&rft.pages=81-86&rft.issn=1476-5810&rft.eissn=1476-5829&rft_id=info:doi/10.1111/j.1476-5829.2010.00208.x&rft_dat=%3Cproquest_cross%3E745636493%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733461556&rft_id=info:pmid/20579320&rfr_iscdi=true |